| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $95,840 | 1 | 33 |
Sells | $17,334 | 2 | 67 |
| SLATTERY JOSEPH P | director | 1 | $95,840 | 0 | $0 | $95,840 |
| Lally Robert B | Principal Accounting Officer | 0 | $0 | 2 | $17,334 | $-17,334 |
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Over the last 12 months, insiders at ImageneBio Inc have bought $95,840 and sold $17,334 worth of ImageneBio Inc stock.
On average, over the past 5 years, insiders at ImageneBio Inc have bought $4.36M and sold $407,403 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SLATTERY JOSEPH P (director) — $95,840.
The last purchase of 16,000 shares for transaction amount of $95,840 was made by SLATTERY JOSEPH P (director) on 2025‑12‑24.
| 2026-07-17 | Sale | Lally Robert B | Principal Accounting Officer | 1,525 0.0134% | $5.34 | $8,144 | -7.43% | |
| 2026-07-16 | Sale | Lally Robert B | Principal Accounting Officer | 1,671 0.015% | $5.50 | $9,191 | -8.26% | |
| 2025-12-24 | SLATTERY JOSEPH P | director | 16,000 0.1287% | $5.99 | $95,840 | -2.39% | ||
| 2025-07-25 | Stampacchia Otello | director | 267,556 10.7425% | $29.90 | $8M | -61.45% | ||
| 2025-07-25 | Bonita David P | director | 83,611 3.357% | $29.90 | $2.5M | -61.45% | ||
| 2022-06-24 | ORBIMED ADVISORS LLC | director | 162,000 1.0796% | $4.96 | $803,975 | -21.69% | ||
| 2022-06-24 | Bonita David P | director | 162,000 1.0796% | $4.96 | $803,975 | -21.69% | ||
| 2022-06-23 | ORBIMED ADVISORS LLC | director | 23,419 0.1167% | $3.71 | $86,884 | +1.45% | ||
| 2022-06-22 | Bonita David P | director | 90,225 0.4351% | $3.59 | $324,046 | +14.75% | ||
| 2022-06-22 | OrbiMed Genesis GP LLC | 66,806 0.3185% | $3.55 | $237,161 | +14.75% | |||
| 2022-06-22 | ORBIMED ADVISORS LLC | director | 66,806 0.3185% | $3.55 | $237,161 | +14.75% | ||
| 2022-01-11 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 964 0.0155% | $12.00 | $11,568 | -63.56% | |
| 2021-12-14 | Sale | FORMELA JEAN FRANCOIS | director | 5,959 0.112% | $14.00 | $83,426 | -63.59% | |
| 2021-12-14 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 5,959 0.112% | $14.00 | $83,426 | -63.59% | |
| 2021-12-13 | Sale | FORMELA JEAN FRANCOIS | director | 8,330 0.1638% | $14.64 | $121,951 | -64.74% | |
| 2021-12-13 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 8,330 0.1638% | $14.64 | $121,951 | -64.74% | |
| 2021-12-10 | Sale | FORMELA JEAN FRANCOIS | director | 11,989 0.242% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 11,989 0.242% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 1,000 0.0198% | $14.76 | $14,760 | -64.33% | |
| 2021-03-30 | ORBIMED ADVISORS LLC | director | 423,400 9.0968% | $16.00 | $6.77M | -49.34% |
| SLATTERY JOSEPH P | director | 16000 0.141% | $64,320.00 | 1 | 0 | |
| ORBIMED ADVISORS LLC | director | 2098097 18.483% | $8.43M | 4 | 0 | <0.0001% |
| OrbiMed Genesis GP LLC | 1912678 16.8496% | $7.69M | 1 | 0 | +14.75% | |
| FORMELA JEAN FRANCOIS | director | 1241935 10.9407% | $4.99M | 1 | 3 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 1241935 10.9407% | $4.99M | 1 | 3 | <0.0001% |
| Stampacchia Otello | director | 454982 4.0081% | $1.83M | 1 | 0 | <0.0001% |
| Bonita David P | director | 287885 2.5361% | $1.16M | 4 | 0 | <0.0001% |
$2,542,362 | 111 | 11.81% | $36.83M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$693,326 | 47 | -16.24% | $40.24M | |
$24,478,755 | 37 | -34.59% | $53.59M | |
$115,646,156 | 35 | 16.45% | $54.05M |
| Increased Positions | 26 | +81.25% | 1M | +26.1% |
| Decreased Positions | 11 | -34.38% | 1M | -25.7% |
| New Positions | 14 | New | 928,718 | New |
| Sold Out Positions | 6 | Sold Out | 1M | Sold Out |
| Total Postitions | 47 | +46.88% | 5M | +0.4% |